[Biological prostheses in the tricuspid position. The immediate and follow-up results].
The results of bioprostheses in the tricuspid position were analysed in 42 patients. 79% were in NYHA class III-IV and 43% had previous cardiac surgery. Concomitant surgical procedures were performed in 86% of the cases. Surgical mortality was 14.3%. Mean follow-up was 54 +/- 31 months. Eight patients were reoperated (5.1%/patient/year), but only 3 for the tricuspid prosthesis. Four patients, with left-sided mechanical prostheses, had systemic thromboembolic events (3.8%/patient/year) and 3 on oral anticoagulation had major haemorrhage (2.8%/patient/year). Primary tricuspid valve dysfunction occurred in two patients (1.2%/patient/year). There were no cases of tricuspid valve thrombosis. For hospital survivors, 5 and 8 years survival was 91.4 +/- 10.3% and 76.2 +/- 10.4%, respectively. The only preoperative predictor of decreased survival was pulmonary artery systolic pressure > or = 50 mmHg. Tricuspid valve replacement with a bioprosthesis was usually performed in the set of multiple-valve operation, with previous cardiac surgery in a high percentage of patients, carrying a significant surgical mortality. However, the long-term survival and the low rate of events related to the tricuspid bioprosthesis favours its use, when conservative surgery is not feasible.
Sousa
L
L
Serviço de Cardiologia, Hospital de Santa Marta, Lisboa.
Soares
R M
RM
Abreu
J
J
Branco
L
L
Agapito
A F
AF
Pedro
A
A
Roquette
J
J
Antunes
A M
AM
D000206:Actuarial Analysis; D000704:Analysis of Variance; D001705:Bioprosthesis / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000401:mortality / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000706:statistics & numerical data; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D011174:Portugal / Q000453:epidemiology; D013997:Time Factors; D014261:Tricuspid Valve
Próteses biológicas em posição tricúspide: resultados imediatos e no follow-up.